viewVerona Pharma

Verona Pharma draft in two new "highly experienced" execs to lead the business into the next phase

David Zaccardelli has replaced Jan-Anders Karlsson as chief executive, while Mark Hahn has been brought in as chief financial officer

Verona Pharma -

Verona Pharma PLC (LON:VRP, NASDAQ:VRNA) said David Zaccardelli has replaced Jan-Anders Karlsson as chief executive, while Mark Hahn has been drafted in as chief financial officer.

The respiratory drugs specialist said Karlsson was retiring after eight years with the company and will pursue non-executive roles, while former CFO, Piers Morgan will remain in place until the end of the month “to provide an efficient transition and complete required financial reporting”.

The two new senior hires have come from Dova Pharmaceuticals, which was last year sold to Swedish Orphan Biovitrum AB in a US$915mln deal.

Verona said Zaccardelli “brings substantial specialty pharmaceutical leadership and operational expertise”, while Hahn, a “seasoned pharmaceutical finance executive”, helped Dova and previous employer Cempra Inc raise over US$600mln in funding.

“They are highly experienced leaders with a proven track record of working together to create significant value for shareholders,” said Verona chairman, Dr David Ebsworth.

“We believe we have a strong team in place to lead Verona Pharma into its next phase of growth.”

The new CEO and CFO will be based in North Carolina along with the majority of the company’s clinical team.

Broker Shore Capital said it was “somewhat surprised” by the management changes, and the market, similarly, appeared to be a little wrong-footed by the announcement as the shares fell 6.7% to 49p.

But Shore, in a note, pointed out: “Both Dr Zaccardelli and Mr Hahn bring significant experience, financial, operational and commercial, to lead Verona through its next phase of late-stage development.

“Further with the senior management team based in the US we would anticipate a more active US capital markets strategy and see this as a positive.”

---adds broker comment---

Quick facts: Verona Pharma

Price: 43.5 GBX

Market: AIM
Market Cap: £46.32 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Verona Pharma named herein, including the promotion by the Company of Verona Pharma in any Content on the Site, the Company receives from said...



Morning Report: Smiths Group halts planned demerger of medical arm

Headlines from the Proactive UK newsroom. Smiths Group (LON:SMIN) has halted the planned demerger of its medical arm due to the coronavirus crisis. Smiths Medical needs to concentrate on the delivery of ventilators and other critical care devices, though the intention remains to separate once...

on 31/3/20

2 min read